Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Inspire Investing LLC

Inspire Investing LLC lifted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,384 shares of the biopharmaceutical company’s stock after buying an additional 3,156 shares during the period. Inspire Investing LLC’s holdings in Agios Pharmaceuticals were worth $407,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares during the period. CWM LLC raised its stake in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Agios Pharmaceuticals by 139.6% during the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,283 shares during the period. Quantbot Technologies LP purchased a new position in Agios Pharmaceuticals in the 3rd quarter valued at $146,000. Finally, Contravisory Investment Management Inc. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at $222,000.

Wall Street Analyst Weigh In

AGIO has been the subject of several recent analyst reports. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Raymond James reissued an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $56.33.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $34.46 on Friday. The stock has a fifty day moving average price of $42.36 and a 200 day moving average price of $44.79. The stock has a market cap of $1.97 billion, a PE ratio of 3.03 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a 1 year low of $21.66 and a 1 year high of $62.58.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.